A phase 3 randomised study of daratumumab plus lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant.
CP-130012
DARZALEX® (DARATUMUMAB) short SPC, click here
CP-130489
